SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026PRNewsWire · 5 days ago
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyPRNewsWire · Oct 8, 2026
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyGlobeNewsWire · Oct 8, 2026
SOPHiA GENETICS (NASDAQ:SOPH) Insider Manuela Valente Sells 4,240 Shares of StockDefense World · Oct 8, 2026
SOPHiA GENETICS (NASDAQ:SOPH) CFO George Cardoza Sells 1,592 Shares of Company StockDefense World · Oct 8, 2026
SOPHiA GENETICS SA (NASDAQ:SOPH) Receives Average Rating of “Hold” from AnalystsDefense World · Oct 6, 2026SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.21 | -$0.26 | Miss |
| May 5, 2026 | -$0.23 | -$0.27 | Miss |
| Mar 3, 2026 | -$0.24 | -$0.28 | Miss |
| Nov 4, 2025 | -$0.20 | -$0.30 | Miss |
| Aug 5, 2025 | -$0.21 | $0.33 | Beat |
| May 6, 2025 | -$0.21 | -$0.26 | Miss |